ClinicalTrials.gg
CompletedNCT05119998Updated Aug 18, 2023

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

A Phase 1 interventional study of IBI325 + sintilimab and IBI325 in Solid Tumor, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI325 in patients with advanced solid tumors

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed, locally advanced unresectable or tumors.
  2. At least one evaluable or per 1.1
  3. Male or female subject at least 18 years old and no more than 75 years old.
  4. Performance Status (ECOG PS) performance status 0 or 1.
  5. Must have adequate organ function
  6. Be able to provide archived or fresh tumor tissues-

Exclusion criteria

Exclusion Criteria:

  1. Previous exposure to any anti-CD73 monoclonal antibody
  2. Subjects participating in another interventional clinical study, except for during the survival follow-up phase of the studies.
  3. Unstable central nervous system netastases
  4. Known active disease or inflammatory disease
  5. Known active infectious disease
  6. Other uncontrolled systematic disease that may increase the risk of participating the study-
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    IBI325 and sintilimab combination does-escalation

    Drug: IBI325 + sintilimab

  • Experimental
    IBI325 monotherapy does-escalation

    Drug: IBI325

Interventions

  • DrugIBI325 + sintilimab

    Drug page: Sintilimab

    IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation

  • DrugIBI325

    IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation

06

What researchers measure

Primary outcomes

  1. Number of patients with DLT

    Number of patients who experienced a dose-limiting toxicity within the first 28 days after the first dose

    Time frame: 28 days post first dose

  2. Number of patients with treatment related AEs

    Number of patients who experienced a treatment related AEs from the first dose until 90days after the last dose

    Time frame: Up to 90 days post last dose

Secondary outcomes

  1. Number of patients with response

    Number of patients with response per RECIST 1.1

    Time frame: Every 6 weeks until progressive disease or up to 24 months after treatment

  2. The area under the curve (AUC)

    Time frame: Up to 90 days post last dose

  3. Maximum concentration (Cmax)

    Time frame: Up to 90 days post last dose

  4. Time at which maximum concentration (Tmax)

    Time frame: Up to 90 days post last dose

  5. The half-life (t1/2)

    Time frame: Up to 90 days post last dose

  6. Positive rate of ADA and Nab

    Time frame: Up to 90 days post last dose

07

Study locations

1 site
  • Shandong Province Cancer Hospital
    Jinan, Shandong 250117, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jul 2023, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2021
First posted
Nov 15, 2021
StartActual
Feb 8, 2022
Primary completionActual
Jul 27, 2023
CompletionActual
Aug 8, 2023
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05119998
Responsible party
Sponsor
First posted
Nov 15, 2021
Start date
Feb 8, 2022
Primary completion
Jul 27, 2023
Completion
Aug 8, 2023
Last update
Aug 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion